Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels As Sustained-Release Scaffolds

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 May 27

PMID 37242726

Authors

Diana Rafael

Marcelo Guerrero

Adolfo Marican

Diego Arango

Bruno Sarmento

Roser Ferrer

Esteban F Duran-Lara

Simon J Clark

Simo Schwartz Jr

Affiliations

Soon will be listed here.

Abstract

Slow-release delivery systems are needed to ensure long-term sustained treatments for retinal diseases such as age-related macular degeneration and diabetic retinopathy, which are currently treated with anti-angiogenic agents that require frequent intraocular injections. These can cause serious co-morbidities for the patients and are far from providing the adequate drug/protein release rates and required pharmacokinetics to sustain prolonged efficacy. This review focuses on the use of hydrogels, particularly on temperature-responsive hydrogels as delivery vehicles for the intravitreal injection of retinal therapies, their advantages and disadvantages for intraocular administration, and the current advances in their use to treat retinal diseases.

Citing Articles

Gene therapy for retinal diseases: From genetics to treatment.

Khaparde A, Mathias G, Poornachandra B, Thirumalesh M, Shetty R, Ghosh A Indian J Ophthalmol. 2024; 72(8):1091-1101.

PMID: 39078952 PMC: 11451791. DOI: 10.4103/IJO.IJO_2902_23.

Seeing the Future: A Review of Ocular Therapy.

Whalen M, Akula M, McNamee S, Deangelis M, Haider N Bioengineering (Basel). 2024; 11(2).

PMID: 38391665 PMC: 10886198. DOI: 10.3390/bioengineering11020179.

References

Ilochonwu B, Urtti A, Hennink W, Vermonden T . Intravitreal hydrogels for sustained release of therapeutic proteins. J Control Release. 2020; 326:419-441. DOI: 10.1016/j.jconrel.2020.07.031. View

Forero-Doria O, Polo E, Marican A, Guzman L, Venegas B, Vijayakumar S . Supramolecular hydrogels based on cellulose for sustained release of therapeutic substances with antimicrobial and wound healing properties. Carbohydr Polym. 2020; 242:116383. DOI: 10.1016/j.carbpol.2020.116383. View

Huang X, Brazel C . On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001; 73(2-3):121-36. DOI: 10.1016/s0168-3659(01)00248-6. View

Alkanaan A, Barsotti R, Kirat O, Khan A, Almubrad T, Akhtar S . Collagen fibrils and proteoglycans of peripheral and central stroma of the keratoconus cornea - Ultrastructure and 3D transmission electron tomography. Sci Rep. 2019; 9(1):19963. PMC: 6934547. DOI: 10.1038/s41598-019-56529-1. View

Dobler E, Mohammed B, Chavan R, Lip P, Mitra A, Mushtaq B . Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results. Eye (Lond). 2022; 37(11):2310-2315. PMC: 9745701. DOI: 10.1038/s41433-022-02338-2. View

Osswald C, Kang-Mieler J . Controlled and Extended Release of a Model Protein from a Microsphere-Hydrogel Drug Delivery System. Ann Biomed Eng. 2015; 43(11):2609-17. DOI: 10.1007/s10439-015-1314-7. View

Sinapis C, Routsias J, Sinapis A, Sinapis D, Agrogiannis G, Pantopoulou A . Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. Clin Ophthalmol. 2011; 5:697-704. PMC: 3104800. DOI: 10.2147/OPTH.S19555. View

Tanihara M, Suzuki Y, Nishimura Y, Suzuki K, Kakimaru Y . Thrombin-sensitive peptide linkers for biological signal-responsive drug release systems. Peptides. 1998; 19(3):421-5. DOI: 10.1016/s0196-9781(97)00420-8. View

Freddo T . A contemporary concept of the blood-aqueous barrier. Prog Retin Eye Res. 2012; 32:181-95. PMC: 3544162. DOI: 10.1016/j.preteyeres.2012.10.004. View

10.

Kuppermann B, Blumenkranz M, Haller J, Williams G, Weinberg D, Chou C . Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007; 125(3):309-17. DOI: 10.1001/archopht.125.3.309. View

11.

Del Amo E, Rimpela A, Heikkinen E, Kari O, Ramsay E, Lajunen T . Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2016; 57:134-185. DOI: 10.1016/j.preteyeres.2016.12.001. View

12.

Wasser L, Weill Y, Brosh K, Magal I, Potter M, Strassman I . The Impact of COVID-19 on Intravitreal Injection Compliance. SN Compr Clin Med. 2020; 2(12):2546-2549. PMC: 7592639. DOI: 10.1007/s42399-020-00614-4. View

13.

Park D, Shah V, Rauck B, Friberg T, Wang Y . An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration. Macromol Biosci. 2013; 13(4):464-9. PMC: 4142681. DOI: 10.1002/mabi.201200384. View

14.

Kunimoto D, Yoon Y, Wykoff C, Chang A, Khurana R, Maturi R . Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology. 2020; 127(10):1331-1344. DOI: 10.1016/j.ophtha.2020.03.035. View

15.

Rong X, Ji Y, Zhu X, Yang J, Qian D, Mo X . Neuroprotective effect of insulin-loaded chitosan nanoparticles/PLGA-PEG-PLGA hydrogel on diabetic retinopathy in rats. Int J Nanomedicine. 2018; 14:45-55. PMC: 6302824. DOI: 10.2147/IJN.S184574. View

16.

Krohne T, Liu Z, Holz F, Meyer C . Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012; 154(4):682-686.e2. DOI: 10.1016/j.ajo.2012.03.047. View

17.

Clark S, Keenan T, Fielder H, Collinson L, Holley R, Merry C . Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera. Invest Ophthalmol Vis Sci. 2011; 52(9):6511-21. PMC: 3175996. DOI: 10.1167/iovs.11-7909. View

18.

Drapala P, Jiang B, Chiu Y, Mieler W, Brey E, Kang-Mieler J . The effect of glutathione as chain transfer agent in PNIPAAm-based thermo-responsive hydrogels for controlled release of proteins. Pharm Res. 2013; 31(3):742-53. DOI: 10.1007/s11095-013-1195-0. View

19.

Ahn S, Hong H, Na Y, Park S, Ahn J, Oh J . Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs. J Vis Exp. 2016; (113). PMC: 5091672. DOI: 10.3791/53878. View

20.

Radhakrishnan K, Sonali N, Moreno M, Nirmal J, Fernandez A, Venkatraman S . Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins. Drug Discov Today. 2016; 22(2):416-423. DOI: 10.1016/j.drudis.2016.10.015. View